News

SGX942 is a first-in-class innate defense regulator (IDR) and is being evaluated as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck

UL EduNeering, a leading provider of quality and compliance training solutions for regulated industries, will educate all CDSCO inspectors and regulators with the UL e-learning modules, co-developed and

The company expects to report preliminary top-line data by the end of the fourth quarter of 2015. PINTA 745 is a peptibody that binds myostatin and inhibits its

The clinical trial, dubbed EVEREST, will evaluate the antiviral activity, safety and pharmacokinetics of a combination regimen of Danoprevir (ASC08), a direct-acting antiviral agent and NS3/4A inhibitor, and

The twice-a-day product can be used in adult males for conditions related with a deficiency or absence of endogenous testosterone (hypogonadism). The company’s oral androgen replacement (SOAR) pivotal

Under the terms of the agreement, Bristol-Myers will pay $150m in cash up front for the right to buy Promedior. Bristol-Myers can exercise its right after Promedior completes

The company will complete screening at participating sites in the next two weeks. Enrollment is anticipated to be completed by the end of the third quarter. Twirla is

Bacterial vaginosis (BV) is the most common vaginal infection in women of childbearing age which is caused due to an imbalance of naturally occurring vaginal bacterial flora. Laccure

Perrigo’s expansive distribution and customer network in the US will be used to boost ScarAway’s growth. ScarAway is expected to have net sales of around $10m in full,